Soiken Holdings (2385) · InitiativeRestated
Developing an AI-Based Imaging Diagnostic for Depression
First written in FY2025. 1 of 2 entries say "Restated". Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Expansion from Biomarker Research into Diagnostic Reagents and Epidemiology ServicesA theme 6 companies write about · 0 as a headwind · 12 as a tailwind
0 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「The Company also focused on developing a new “diagnostic product for depression” using imaging AI technology and actively pursued research aimed at putting its research results into practical use in society.」
The Company continues to pursue research and development of an imaging AI-based diagnostic product for depression and efforts to put it into practical use in society. - FY2025First statedAnnual report
「The Company also focused on developing a new “diagnostic product for depression” using imaging AI technology and actively pursued research aimed at putting its research results into practical use in society.」
In addition to its conventional research and development, including fatigue assessment, the Company identified the development of an imaging AI-based diagnostic product for depression as a new theme for putting research into practical use in society.